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Dual induction with low doses of rabbit anti-human thymoglobulin (RATG) and basiliximab eﬀectively and safely prevented
allograft rejection in high-risk renal transplant recipients. To assess whether treatment timing aﬀects eﬃcacy and tolerability,
in this single-center, matched-cohort study, we compared posttransplant outcomes in 25 patients and 50 gender-, age-, and
treatment-matched reference patients induced with the same course of 7 daily RATG infusions (0.5mg/kg/day) started before or
after engraftment, respectively. All subjects received basiliximab (20mg) before and 4 days after transplantation, withdrew steroids
within 6 days after surgery, and were maintained on steroid-free immunosuppression with cyclosporine and mycophenolate
mofetil or azathioprine. Over 12 months after transplant, 1 patient (4%) and 13 reference patients (26%) had acute rejection
episodes. One patient and 5 reference-patients required dialysis therapy because of delayed graft function. In all patients
circulating CD4+ and CD8+ T lymphocytes were fully depleted before engraftment. Both treatments were well tolerated. In kidney
transplantation, perioperative RATG infusion enhances the protective eﬀect of low-dose RATG and basiliximab induction against
graft rejection and delayed function, possibly because of more eﬀective inhibition of early interactions between circulating T cells
and graft antigens.
1. Introduction
Induction therapy with early administration of antilympho-
cyte antibodies has been introduced into clinical transplan-
tation to modify the host immune response at the time
of donor antigen presentation. This approach is aimed at
achieving immune hyporesponsiveness of the host expected
to translate into a reduced risk of rejection in the posttrans-
plant period [1, 2]. Diﬀerent antibodies have been used for
induction therapy, including monoclonal nondepleting anti-
bodies such as basiliximab and daclizumab, and monoclonal
or polyclonal depleting antibodies, such as alemtuzumab or
thymoglobulin, respectively [1, 2].
Nondepleting are safer than depleting antibodies, but
are less eﬀective [3]. Depleting antibodies may cause severe
adverse events including infusion-related cytokine-release
syndrome and enhanced risk of CMV reactivations and lym-
phoproliferative disorders in the long term [4, 5]. To mini-
mize side eﬀects, we introduced in our clinical practice an
induction strategy based on rabbit anti-human thymoglobu-
lins (RATGs) administered at very low doses (approximately
half the currently recommended doses for induction and
one-third to one-fourth of doses administered in the large
majority of previous reports [3, 6, 7]). To avoid the risk of
insuﬃcient antirejection activity, we integrated this regimen
with basiliximab, an anti-interleukin-2 receptor (IL-2R)
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monoclonal antibody administered with the rationale of
inhibiting those lymphocytes eventually surviving low-dose
RATG exposure.
In a randomized, prospective study, we showed that this
dual induction protocol, compared to the standard single-
drug, full-dose RATG regimen, provided the same protective
eﬀect against acute allograft rejection in hyperimmune renal
transplant patients and in those with delayed graft function
(DGF), but was better tolerated [8]. On the basis of these
encouraging findings, since October 2004 we applied the
dual induction regimen to all new incident patients receiving
a kidney transplant at our Institution. Steroids were tapered
and withdrawn within 6 days after transplant and patients
were maintained on low doses of Cyclosporine A (CsA) and
randomly allocated to mycophenolate mofetil (MMF) or
azathioprine (AZA), in the setting of an immunosuppressive
regimen aimed at achieving eﬀective prevention of allograft
rejection with minimized risk of side eﬀects.
In themeantime, however, evidence has become available
that, in addition to the adopted treatments, the timing of
treatment administration may aﬀect the eﬀectiveness of in-
duction therapy. A randomized clinical trial [9] found that in
adult deceased donor renal transplant recipients, RATG infu-
sion started before graft reperfusion was associated with a
reduced DGF incidence compared to posttransplant admin-
istration of the same RATG regimen [9]. The authors sug-
gested that DGF prevention could be explained by inhibited
production and activity of adhesionmolecules, which in turn
limited leukocyte rolling and adhesion along capillary endo-
thelial surfaces, one of the early interactions between the host
and the graft leading to ischemia-reperfusion injury [10].
Early interaction between circulating lymphocytes and
the engrafted organ may also initiate the sequence of events
mediating the immune response of the host that can even-
tually result in graft rejection [11]. Thus, we hypothesized
that preengraftment depletion of circulating lymphocytes
achieved by perioperative RATG administration, in addition
to limit the risk of DGF, could also prevent subsequent
activation of the immune response and eventual graft
rejection [9]. To formally test this hypothesis, we compared,
in the setting of a matched-cohort study, the outcomes
of 25 consecutive patients who had received a low-dose
RATG infusion started before referral to the surgical room
with those of 50 gender- and age-matched controls who
received the same RATG regimen started after surgery, in
combination with the same basiliximab induction and back-
ground maintenance immunosuppression. We secondarily
explored whether improved outcomes—if any—achieved by
peritransplant induction could be explained by early T-cell
depletion.
2. Materials and Methods
2.1. Study Protocol. Since October 2004, all consecutive
patients receiving a kidney transplant from deceased donors
at the Bergamo Transplant Center were induced with
basiliximab in combination with a seven-day course of
RATG that was started after surgery, at patient referral to our
Nephrology Unit. Since May 2009, the same induction
regimen was started before engraftment, as soon as the
patient was assigned to receive the transplant. No change
was introduced in concomitant maintenance immunosup-
pressive regimen. Thus, in the present study, we compared
clinical outcomes of 21 consecutive patients who received
perioperative RATG with those of 42 gender-, age- (±10
years) and treatment- (MMF or AZA) matched reference
patients who had received the first RATG dose after
surgery. Secondarily, we evaluated changes in circulating T
lymphocytes achieved by perioperative RATG infusion to
explore the relationship between T-cell counts and clinical
outcomes. Outcome data were retrieved from each individual
patient up to last available followup and from each couple
of corresponding reference-patients throughout the same
posttransplant observation period.
Living donor recipients, patients with a peak panel reac-
tive antibody titer >30%, or patients receiving multiorgan
transplants were not considered, since they were treated, as
per center practice, with a diﬀerent maintenance immuno-
suppressive regimen [8]. No changes in selection criteria of
donors and recipients, center surgical and medical equips,
or surgical and monitoring procedures, were introduced
throughout the whole study period.
Treatment. Patients received eight-hour daily intravenous
infusions of 0.5mg/kg of RATG (Thymoglobulin, Genzyme
corporation, Italy) from the transplant day to day 6 after
transplant. The first infusion was started in the Nephrology
Unit and was continued during and after the surgical
procedure until the administration of the prescribed dose
was completed. As previously described [8], the infusion was
preceded by the intravenous injection of methylprednisolone
(500mg) and chlorphenamine (10mg) to prevent acute
cytokine release syndrome. The daily doses of RATG were
reduced or temporarily withdrew when white blood cell
or platelet counts decreased to <2,000/μL or <50,000/μL,
respectively. A fixed dose of 20mg of Basiliximab (Simulect,
Novartis, Italy) was administered on day 0 before methyl-
prednisolone infusion and 4 days apart. Methylprednisolone
250mg were infused on day 1, 125mg on day 2 after
transplant, followed by 75mg, 50mg, and 25mg of oral pre-
dnisone administered on posttransplant days 3, 4 and 5,
respectively. Thereafter, all subjects were oﬀ steroids.
All patients received maintenance immunosuppression
with CsA (Sandimmune, Novartis, Italy) given at daily doses
targeting blood trough levels between 300 and 400 ng/mL
from day 0 to day 7, 200 and 250 ng/mL from day 8 to 30,
150 to 200 ng/mL up to month 6 posttransplant and 100
to 150 ng/mL thereafter. MMF (1.5 g/day; Cell Cept, Roche,
Italy) or AZA (125mg/day if body weight > 75 kg, 75mg/day
if≤75 kg; Imuran, GlaxoSmithKline, Italy) was administered
in a random sequence starting on posttransplant day 1.
Doses were reduced if white blood cells and platelet counts
decreased to <2,000/μL or <50,000/μL, respectively.
Reference-patients received the same induction and
maintenance therapy described above for study patients with
the only exception that the first RATG infusion was started
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postoperatively, when they were referred to the Nephrology
Unit (about 30 minutes after the end of the surgery).
Monitoring and Followup. All patients and reference-patients
were followed according to the same monitoring protocol.
Routine clinical and laboratory parameters, including glom-
erular filtration rate (eGFR) estimated by the Walser equa-
tion [12], were evaluated daily up to after transplant day 14,
every other day up to month 1, every week up to month 3,
and monthly thereafter. Blood CsA concentrations were
measured daily up to after transplant day 14 and monthly
thereafter.
In patients, circulating T lymphocytes and CD3+CD4+
and CD3+D8+ T cells were counted by fluorescence-assisted
cell-sorter analysis before and immediately after the first
steroid infusion (i.e., before starting RATG infusion), one
hour after the start of RATG infusion, immediately before
graft reperfusion, at 10 and 24 hours after the initial
sampling, and at 7, 14, 180, and 360 days posttransplant.
Reference-patients had the same evaluations before infusion
of steroids and RATG, and at 7, 14, 180, and 360 days
posttransplant.
Acute Rejection. Clinical diagnosis was established on the
basis of the following criteria: a transient increase in
serum creatinine concentration (>0.3mg/dL) not obviously
explained by cyclosporine trough levels above the target
range or by kidney hypoperfusion, vascular thrombosis, or
urinary tract obstruction. Clinical diagnosis was confirmed
by evidence of renal function recovery following a standard
course of intravenous steroid pulses (methylprednisolone
500mg/day for 3 days, progressively tapered to the main-
tenance oral dose over 10 days) [8]. A kidney biopsy
was performed per protocol to confirm or exclude the
clinical diagnosis of acute rejection in those patients with
a kidney function that did not recover within 3–5 day of
steroid therapy. A bioptic diagnosis of acute rejection was
established according to Banﬀ criteria. In all patients who
had a kidney biopsy performed to verify a clinical diagnosis
of acute graft rejection, the diagnosis was confirmed by the
histology findings.
Delayed Graft Function. DGF was defined as need for dialysis
therapy within the first week after transplant [8]. In DGF
patients, initiation of CsA was delayed and steroid treat-
ment was prolonged until serum creatinine spontaneously
declined [13]. A graft biopsy sample was taken 7 days after
transplant from subjects who remained dialysis dependent
to assess the causes of persisting graft dysfunction.
Cytomegalovirus Reactivation. Cytomegalovirus (CMV) re-
activations were monitored by measuring CMVpp65 anti-
genemia or CMD DNAemia (since November 2007) by a
commercial CMV-PCR method (Cobas Amplicor Monitor)
and were treated by intravenous ganciclovir or oral valganci-
clovir [8].
2.2. Statistical Analysis. Baseline recipients’ and donors’
characteristics were compared between groups by t-test, χ2,
or Fisher’s exact test as appropriate. For each parameter,
changes over time and diﬀerences between groups were
assessed by either analysis of variance (ANOVA) for repeated
measures or ANOVA factorial, or analysis of covariance
(ANCOVA), as appropriate. Time to acute rejection was
compared between groups by log-rank test. Univariable
analyses were performed to assess whether baseline variables
or CsA levels at diﬀerent times after transplant were signifi-
cantly associated with the risk of acute rejection.Mechanisms
possibly explaining the observed treatment eﬀects on acute
rejection were explored by including in the models CsA
trough levels during the first week after transplant, consid-
ered separately.
Data are expressed as mean ± SD or median (interquar-
tile range) if not otherwise indicated. Statistical analyses were
accomplished with SAS software (version 9.1; SAS Institute,
Cary, NC). All statistical analyses were by two-tailed tests.
The statistical level of significance was P < 0.05.
3. Results
At transplantation, characteristics of patients and reference-
patients and of their corresponding donors were similar, with
the only exception of less HLA-B mismatches in patients
(Table 1). Twelve (48%) patients and 39 (78%) reference-
patients were on MMF therapy (P = 0.017). All patients and
reference-patients were followedup until the end of the first
year after transplant.
3.1. Eﬃcacy Outcomes. At study end, all subjects were alive
with a functioning graft.
Allograft Rejection. Overall, 14 of the 75 study subjects
(18.7%) had one allograft rejection. Rejection episodes
occurred in one of the 25 patients and 13 of the 50 reference-
patients (4% versus 17.3%, P = 0.02, Figure 1). One patient
versus six reference-patients received a graft biopsy, since
their serum creatinine did not decline after the first steroid
pulses. In all these cases, the clinical diagnosis of acute
rejection was confirmed by histological analysis and renal
function eventually recovered with steroid therapy alone.
Banﬀ scores were 1A for the single patient and borderline
(n = 2), 1A (n = 1), 2A (n = 1), and 2B (n = 2) for the six
reference-patients. None of considered donor and recipient
characteristics (including the number of mismatches), nor
CsA trough levels during the whole follow-up period were
significantly associated with the risk of rejection.
Renal Function Recovery. Kidney function promptly recov-
ered in all patients, whereas 5 reference-patients required 1 or
2 dialysis sessions because of DGF (P = 0.16). eGFR tended
to be higher in patients than in reference-patients both at
seven days (50.4 ± 24.5 versus 45.6 ± 26.6mL/min/1.73m2,
P = 0.44) and at 12 months (56.2 ± 15.3 versus 52.0 ±
14.0mL/min/1.73m2, P = 0.25) after transplant.
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Table 1: Baseline characteristics of donors and recipients.
Overall
(n = 75)
Patients
(n = 25)
Reference-
patients
(n = 50)
Donors
Males (%) 37 (49.3) 12 (48) 25 (50)
Age (yrs) 48.0± 13.1 46.9± 11.8 48.9± 13.8
Weight (Kg) 72.0± 14.6 73.3± 16.9 71.3± 13.5
Mismatches
A 0.9± 0.6 0.8± 0.8 0.9± 0.5
B 1.3± 0.7 1.0± 0.6∗ 1.4± 0.7
DR 1.2± 0.6 1.0± 0.6 1.2± 0.6
Recipients
Males (%) 48 (64) 16 (64) 32 (64)
Age (yrs) 49.3± 10.9 51.5± 11.4 48.2± 10.6
Weight (Kg) 67.4± 13.5 70.7±
14.3∗
65.7± 12.9
Cold ischemia time (h) 14.7± 7.1 15.7± 6.9 14.3± 7.2
Causes of ESRD
Hypertension,
renovascular disease
4 (5.3%) 3 (12%) 1 (2%)
Glomerulonephritis 20 (26.7%) 7 (28%) 13 (26%)
Polycystic kidney disease 12 (16%) 4 (16%) 8 (16%)
Other 18 (24%) 7 (28%) 11 (22%)
Unknown 21 (28%) 4 (16%) 17 (34%)
Data are numbers (percent) or mean ± SD. ∗P < 0.05 versus reference-
patients.
Circulating T Lymphocyte Counts. Total circulating T lym-
phocytes, and CD4+ and CD8+ cells considered sepa-
rately, did not change appreciably across methylprednisolone
infusion. However, they were almost fully depleted over
one-hour RATG infusion and no circulating lymphocytes
were detectable in any single patient from the sampling
preceding the engraftment (approximately after four hours
of RATG infusion) up to the one preceding the second RATG
infusion on after transplant day 1 (Figure 2). In both groups
circulating T cells were still remarkably reduced at two weeks
after transplant and showed a similar trend to recover toward
normal range over 6–9 months posttransplant (data not
shown).
3.2. Immunosuppressive Therapy. Cyclosporine trough levels
were significantly higher in patients than in reference-
patients at 3, 4, 5, and 6 days after transplant, but were similar
between groups thereafter. The initial diﬀerence was fully
explained by the fact that in the five reference-patients with
DGF, CsA treatment was postponed by an average of 5.8 days.
None of these subjects was rejected on subsequent followup.
When analyses were restricted to subjects without DGF, CsA
trough levels were similar between treatment groups also
during the first week after transplant. CsA levels in subjects
with or without allograft rejection considered independently
from timing of RATG infusion were similar as well. Mean
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Figure 1: Kaplan-Meier curves of the percentages of patients and
reference-patients with acute rejection during the whole follow-up
period.
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Figure 2: Circulating total T lymphocytes, CD4+ and CD8+ T-
cell counts before and at diﬀerent time points after the start of
Thymoglobulim infusion in the 25 patients. All diﬀerences between
pre- and post-RATG counts were statistically significant (∗P <
0.005).
MMF and AZA doses were similar between groups during
the whole follow-up period (data not shown).
3.3. Safety. No cytokine release syndrome symptoms were
observed during induction therapy with the only exception
of mild and self-limiting fever observed during the first
RATG infusion in 17 (34%) reference-patients, but never
in patients (P = 0.001). Four patients (16%) and 8
reference-patients (16%) had at least one episode of transient
leukopenia that always recovered after RATG, MMF, or AZA
dose reduction.
The overall incidence of CMV reactivations was sig-
nificantly lower in patients compared to reference-patients
(Table 2), even when analyses were restricted to the 25
patients and 14 reference-patients evaluated by the same
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Table 2: Main adverse events after transplant in the two study
groups.
Patients
(n = 25)
Reference-patients
(n = 50)
Acute rejections—n (%) 1 (4.0)∗ 13 (26.0)
DGF—n (%) 1 (4.0) 5 (10.0)
N. of dialyses 2 1 (1-2)
Leukopenia—n (%) 4 (16) 8 (16)
Thrombocytopenia—n (%) 0 1 (2)
CMV reactivations—n (%) 5 (20)∗ 27 (54.0)
CMV DNA 5/25 (20) 8/14 (57.1)
Ag PP65 — 19/36 (52.7)
Data are number (percentage) or median (range). DGF: delayed graft
function, leukopenia: leukocytes < 3000/mm3, thrombocytopenia: platelets
< 50,000/mm3, ∗P < 0.05 versus reference-patients.
diagnostic procedure based on the measurement of CMV
DNAemia (Table 2). All reactivations were observed within
the first three months after transplant and fully recovered
with ganciclovir or valganciclovir therapy.
4. Discussion
In our present series of deceased-donor renal transplant
recipients, the overall incidence of acute rejections following
dual induction therapy with low-dose RATG and basiliximab
was remarkably low despite early steroid withdrawal and
steroid-free maintenance therapy with low doses of CsA
given in combination with MMF or AZA. The novel finding
here was that timing of RATG administration in the setting
of dual induction therapy remarkably aﬀected posttransplant
outcomes. Indeed, only one of the 25 patients receiving
perioperative RATG infusion had an acute allograft rejection
compared to 13 of the 50 reference-patients receiving RATG
infusion after transplant. Moreover, the 5 cases of delayed
graft function were all restricted to the reference-patient
population. Of note, the incidence of rejections we observed
following perioperative RATG administration was amongst
the lowest incidences reported in kidney transplantation [3,
14], which is of some relevance considering that this outcome
was achieved in the setting of a steroid-free maintenance
regimen by RATG cumulative doses that were approximately
one-quarter of those employed in most previous series [6, 7]
and one-half of those currently recommended in clinical
transplantation [3].
We also found that the protective eﬀect against allograft
rejection achieved by perioperative RATG administration
was associated with a prompt and complete depletion of T
lymphocytes from the circulation that ensued over the first
hour of RATG infusion and persisted for at least two weeks
after transplant. This might have facilitated the establishment
of a protolerogenic milieu since, after complete deple-
tion, regenerating alloantigen-specific T cells most likely
encountered the graft antigens in a healed state, when they
were purportedly reinforced to become anergic [11]. This
might explain the eﬀective prevention of allograft rejection
we observed in our patients [11]. Indeed, thymoglobulins
may facilitate a protolerogenic state through depletional
and nondepletional mechanisms [15, 16], involving the
modulation of B lymphocyte, dendritic cell, and natural
killer T-cell activity [17, 18]. They also promote conversion
of CD4+CD25−T cells into CD4+CD25+ regulatory T cells
[16]. This eﬀect, however, is at least in part mediated by
interleukin 2 (IL-2) activity [19] and might have been
limited by concomitant Il-2 inhibition achieved by basil-
iximab. Actually, per-protocol basiliximab coadministration
was intended to inhibit those T cells that survived the very
low doses of RATG we infused in our subjects. Finding that
T lymphocytes were fully depleted from the circulation for
at least two weeks after transplantation, a posteriori suggests
that basiliximab will unlikely complement the antirejection
activity of low-dose RATG and might just inhibit RATG-
induced expansion of CD4+CD25+ regulatory T cells. This
hypothesis merits to be addressed by ad hoc trials comparing
the antirejection activity of RATG induction with or without
concomitant basiliximab therapy.
The protective eﬀect of perioperative RATG infusion
against DGF is also worth mentioning. Both RATG and
IL-2R antagonists reduce the ischemia/reperfusion injury,
possibly by blocking integrin expression on endothelial and
T cells and by inhibiting leukocyte adherence to the vessel
walls [9, 20–22]. Thus, with dual induction the two drugs
could synergistically contribute to accelerate posttransplant
renal function recovery. On the other hand, none of the five
reference-patients with DGF eventually had acute rejection
despite postponed CsA administration. Thus, the excess risk
of acute rejection observed with posttransplant compared to
perioperative RATG infusion could not be explained by less
eﬃcient calcineurin inhibition in reference-patients. This is
consistent with evidence that when DGF subjects were not
considered in the analyses, CsA through levels were virtually
identical between treatment groups throughout the whole
observation period.
Of note, early RATG administration did not aﬀect
the remarkably good safety profile we previously observed
with basiliximab combined to postoperative low-dose RATG
infusion [8]. In our present series, no subject had signs
of cytokine release syndrome such as chills, hypotension,
or severe leukopenia or thrombocytopenia, with the only
exception of a mild and self-limiting fever that was observed
in some reference-patients during the first RATG infusion,
but never in patients. Anesthesia could have masked some
cytokine release-related events in the patient cohort. On
the other hand, it should be also considered that patients
who received pre-transplant RATG administration had the
infusion shortly anticipated by steroid administration. Con-
versely, when RATGs were administered after surgery, the
anti-inflammatory eﬀect of pre-transplant steroid infusion
was largely vanished, which could explain the increased
incidence of fever. Regardless of the above, patients who
received pre-transplant RATG infusion had less frequently
fever after surgery, which made their post-operative man-
agement easier. These findings are of clinical interest, since
acute treatment-related adverse events are reported in 40
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to 60 percent of patients during infusion of conventional
doses of RATG and may require treatment adjustments
that may limit the antirejection eﬃcacy of induction ther-
apy [4, 5]. Minimized maintenance immunosuppression,
together with the small doses of RATG we administered
for induction, might also have contributed to the excellent
tolerability of our treatment regimen throughout the whole
study period. An unexpected finding of the present study
was the significantly lower incidence of CMV reactivations
observed in patients compared to reference-patients, even
when analysis was restricted to those subjects evaluated by
the same diagnostic procedure based on the measurement of
CMVDNAemia. Since induction andmaintenance immuno-
suppression regimens were the same for all study subjects,
whereas only one patient compared to 13 reference-patients
required steroid pulse therapy for the treatment of acute graft
rejection, the above findings were most likely explained by
reduced patient exposure to steroid, an additional potential
benefit of perioperative induction therapy.
The major limitations of our present study were the
relatively small sample size and the nonrandomized design.
Major strengths were the controlled design with a rigorous
matching between patients and reference-patients by pre-
defined criteria and the standardized treatment andmonitor-
ing guidelines that were applied to all study subjects by the
same team at the same institution. These factors altogether
contributed to avoid preventable sources of bias. Moreover,
serial T-cell counts allowed for the first time to monitor the
lymphocytolytic activity of low-dose RATG induction and
to explore its clinical implications in the setting of kidney
transplantation.
5. Conclusions
In renal transplant recipients on a steroid-free maintenance
immunosuppressive therapy with low-dose CsA combined
to MMF or AZA, the protective eﬀect of dual induction
therapy with low-dose RATG and basiliximab against acute
allograft rejection and DGF was enhanced when the first
infusion of RATG was started before graft reperfusion.
Improved outcomes were likely explained by pretransplant
depletion of circulating T cells. Finding that prompt and
profound T-cell depletion was already achieved during
the first pre-transplant RATG administration, combined
to evidence that the depleting eﬀect of one single RATG
administration is sustained over time [23, 24], provides the
background for further studies to assess whether repeated
RATG infusions are actually needed to maintain a sustained
host hyporesponsiveness against the graft. This is an issue
of major clinical relevance since further minimization of
induction therapy, combined with minimized maintenance
immunosuppression, might help further in improving the
risk/benefit profile of antirejection treatment in clinical
transplantation. Whether peritransplant administration of
very low RATG doses allows preventing acute rejection
with minimal immunosuppression independent of add-on
basiliximab therapy is the subject of an ongoing further
study.
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